Michael S. Cuffe, an officer of HCA Healthcare, Inc., filed a Form 144 notice on October 29, 2026, proposing the sale of 11,800 shares of HCA Healthcare common stock on the New York Stock Exchange through Merrill Lynch.

Key Highlights

  • Proposed seller: Michael S. Cuffe, identified as an officer of HCA Healthcare, Inc.
  • Shares proposed for sale: 11,800 shares of common stock, with an aggregate market value of $5,628,600.
  • Approximate date of sale: October 29, 2026, through broker Merrill Lynch in Atlanta, Georgia.
  • Shares outstanding: 216,501,500 shares of common stock reported outstanding at the time of filing.
  • Sources of shares: 1,747 shares from a Performance Award Vest on February 13, 2025; 6,127 shares from a Performance Award Vest on February 10, 2026; and 3,926 shares from an Exercise of a Stock Appreciation Right on October 29, 2026, all acquired from HCA Healthcare, Inc. as compensatory payments.
  • Prior three-month sales: Nothing to report, according to the filing.

Cuffe's Proposed Rule 144 Sale: Sources and Details

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Michael S. Cuffe, an officer of HCA Healthcare, Inc. (NYSE:HCA), proposed to sell 11,800 shares of the company's common stock. The filing lists the aggregate market value of the proposed sale at $5,628,600. The broker named in the filing is Merrill Lynch, located at 3455 Peachtree Road NE Suite 1000, Atlanta, GA 30326.

The filing discloses three separate acquisition events underlying the shares proposed for sale. A total of 1,747 shares were acquired through a Performance Award Vest on February 13, 2025, and 6,127 shares through a Performance Award Vest on February 10, 2026, both from HCA Healthcare, Inc. as compensatory payment. An additional 3,926 shares were acquired on October 29, 2026, through the exercise of a Stock Appreciation Right, also from HCA Healthcare, Inc. as compensatory payment. The filing notes a typographical variation in the issuer name for the third entry, listed as "HCA Helathcare, Inc."

The filing states that no securities of HCA Healthcare were sold during the three months preceding the notice date. By signing the Form 144, Cuffe represented that he does not know any material adverse information regarding the current and prospective operations of HCA Healthcare that has not been publicly disclosed.

What Was Disclosed

HCA Healthcare officer Michael S. Cuffe filed a Rule 144 notice proposing the sale of 11,800 common shares, valued at $5,628,600 in aggregate, through Merrill Lynch on October 29, 2026. All shares originated from compensatory performance awards and a stock appreciation right exercise.